Combined therapy with deferiprone and deferoxamine (from Liu20).
| . | . | . | . | . | . | . | UIE (mg/24h or mg/kg/d) . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| . | No. . | Duration (months) . | DFP dose (mg/kg/d) . | DFO dose (/d) . | DFO d/wk . | DFP . | DFO . | DFP + DFO . | Initial . | Final . | Significance . |
| Abbreviations: DFO, deferoxamine; DFP, deferiprone; HCV, hepatitis C virus; ng, not given; ns, not significant; UIE, urine iron excretion. | |||||||||||
| †One additional patient withdrew after 1 month because of gastrointestinal symptoms. | |||||||||||
| ‡Significant improvement in ventricular dimensions and function and increase in myocardial T2 relaxation time. | |||||||||||
| §Agranulocytosis in 2 patients reversed after 4–5 days; 1 withdrawal with nausea. Transient moderate ALT rise in 6 HCV-negative and 12 HCV-positive patients. One stopped therapy. | |||||||||||
| *Agranulocytosis in 2 patients—reversed with drug discontinuation. | |||||||||||
| Wonke et al31 | 5 | 6 | 75–110 | 2 g | 2–6 | 23 | 36 | 70 | 6397 | 2439 | ns |
| Balveer et al39 | 7† | 12 | 75–85 | 1 g | 2 | 14 | — | 27 | 6619 | 3996 | P < .01 |
| Mourad et al40 | 11 | 12 | 75 | 2 g | 2 | — | — | 49 | 4153 | 2805 | P < .01 |
| Farmaki et al41 | 40‡ | 6–12 | 75–100 | 40–60 | 2–6 | — | — | — | 1907 | 385 | ng |
| Alymara et al42 | 21 | 6 | 60 | 50 mg/kg | 6 | — | 0.34 | 0.76 | 3146 | 1799 | ng |
| Galanello et al43 | 34 | 3–10 | 75 | 20–50 | 2–5 | 0.37 | 0.48 | 0.77 | 5097 | 3963 | ng |
| Kattamis et al44 | 18* | 12 | 50 | 2.53–3.0 g | 3 | 0.50 | 0.46 | 0.69 | 4543 | 3297 | P < .007 |
| . | . | . | . | . | . | . | UIE (mg/24h or mg/kg/d) . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| . | No. . | Duration (months) . | DFP dose (mg/kg/d) . | DFO dose (/d) . | DFO d/wk . | DFP . | DFO . | DFP + DFO . | Initial . | Final . | Significance . |
| Abbreviations: DFO, deferoxamine; DFP, deferiprone; HCV, hepatitis C virus; ng, not given; ns, not significant; UIE, urine iron excretion. | |||||||||||
| †One additional patient withdrew after 1 month because of gastrointestinal symptoms. | |||||||||||
| ‡Significant improvement in ventricular dimensions and function and increase in myocardial T2 relaxation time. | |||||||||||
| §Agranulocytosis in 2 patients reversed after 4–5 days; 1 withdrawal with nausea. Transient moderate ALT rise in 6 HCV-negative and 12 HCV-positive patients. One stopped therapy. | |||||||||||
| *Agranulocytosis in 2 patients—reversed with drug discontinuation. | |||||||||||
| Wonke et al31 | 5 | 6 | 75–110 | 2 g | 2–6 | 23 | 36 | 70 | 6397 | 2439 | ns |
| Balveer et al39 | 7† | 12 | 75–85 | 1 g | 2 | 14 | — | 27 | 6619 | 3996 | P < .01 |
| Mourad et al40 | 11 | 12 | 75 | 2 g | 2 | — | — | 49 | 4153 | 2805 | P < .01 |
| Farmaki et al41 | 40‡ | 6–12 | 75–100 | 40–60 | 2–6 | — | — | — | 1907 | 385 | ng |
| Alymara et al42 | 21 | 6 | 60 | 50 mg/kg | 6 | — | 0.34 | 0.76 | 3146 | 1799 | ng |
| Galanello et al43 | 34 | 3–10 | 75 | 20–50 | 2–5 | 0.37 | 0.48 | 0.77 | 5097 | 3963 | ng |
| Kattamis et al44 | 18* | 12 | 50 | 2.53–3.0 g | 3 | 0.50 | 0.46 | 0.69 | 4543 | 3297 | P < .007 |